2024
Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome
Singhal S, Riggs E, Ruth K, Chavez-Salas J, Chertock Y, Daly M, Hall M. Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology 2024, 8: e2400562. PMID: 39546469, PMCID: PMC11573245, DOI: 10.1200/po-24-00562.Peer-Reviewed Original ResearchConceptsLynch syndromeLifetime risk of colorectal cancerColorectal cancerRisk of colorectal cancerCancer prevention optionsFactors associated with useNonsteroidal anti-inflammatory drugsDisease-related factorsChemoprevention uptakeScreening behaviorAspirin chemopreventionRelative risk reductionResearch invitationsPatients' perceptionsLifetime riskAdvocacy websitesASA/NSAID useElectronic surveyFox Chase Cancer CenterPrevention optionsCancer CenterRisk reductionMultivariate modelChemopreventive benefitsParticipantsPerceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample.
Hall M, Singhal S, Osorio N, Chavez J, Riggs E, Chertock Y, Daly M. Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample. Journal Of Clinical Oncology 2024, 42: 77-77. DOI: 10.1200/jco.2024.42.3_suppl.77.Peer-Reviewed Original ResearchLynch syndromeCancer prevention optionsCA riskNon-usersOne-time surveySupport groupsConvenience sampleCA preventionStratified analysisFox Chase Cancer CenterNegative public attitudesPrevention optionsColonoscopyMSI-H tumorsCA-PTPerceptions of efficacyCancer CenterSide-effect riskPersonal historyBelief statementsSide effect concernsInternational patientsSide effectsMSI-HRisk
2010
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli N, Daly M, Feldman G. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics In Medicine 2010, 12: 245-259. PMID: 20216074, DOI: 10.1097/gim.0b013e3181d38f2f.Peer-Reviewed Original ResearchConceptsBRCA1/2 mutationsBRCA2 mutationsHereditary breastTesting of at-risk relativesFamily history of cancerOvarian cancerAt-risk relativesPrimary prevention optionsHistory of cancerPrevalence of BRCA1/2 mutationsEstimates of penetranceAshkenazi Jewish populationCancer riskProphylactic surgeryPrevention optionsFamily historyBRCA2 genesEarly interventionFamily membersBRCA2Increased surveillanceFamilial mutationsBRCA1/2BRCA1Jewish population